SCD1 inhibitor-3 is primarily utilized in research focused on metabolic disorders and cancer. It targets the enzyme stearoyl-CoA desaturase-1 (SCD1), which plays a key role in lipid metabolism. By inhibiting SCD1, it helps reduce the production of certain fatty acids, making it a potential candidate for studying obesity, diabetes, and non-alcoholic fatty liver disease (NAFLD). Additionally, its role in cancer research is significant, as SCD1 inhibition can disrupt lipid synthesis in cancer cells, potentially slowing tumor growth. This compound is also explored for its effects on skin conditions, as modulating lipid composition can influence skin health and diseases like acne. Overall, it serves as a valuable tool in understanding metabolic pathways and developing therapeutic strategies.